Stock Market Reviews

BRNS (Barinthus Biotherapeutics plc) News

Get the latest news, insights, and market updates on BRNS (Barinthus Biotherapeutics plc). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Buy: What Does It Mean for the Stock?
  Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
  Dec 15, 2025 - $BRNS
• Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
  VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trialVTP-1000 was well-tolerated with no treatment-related SAEs The MAD portion of the trial, which includes a gluten challenge, is ongoing GERMANTOWN, Md., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), an immunology and inflammation (“I&I”) company focused on developing immune tolerance
  Dec 10, 2025 - $BRNS
• Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments
  Single ascending dose data readout for VTP-1000 expected before the end of 2025Enrollment advancing in multiple ascending dose part of the AVALON trial; data expected in the second half of 2026Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) to strengthen and diversify the pipeline and broaden the Company’s base of high caliber institutional investors. GERMANTOWN, Md., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Compan
  Nov 7, 2025 - $BRNS
• ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics
  ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry, computational, and clinical pharmacology support to Clywedog Therapeutics as the company enters into a definitive merger agreement with Barinthus Therapeutics (NASDAQ: BRNS). The combined entity will operate under the name Clywedog Therapeutics, Inc. and is expected to list on Nasdaq under the ticker CLYD upon closing. The merged portfolio will focus on advancing clinical
  Oct 24, 2025 - $BRNS
• Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases
  GERMANTOWN, MD and ALTRINCHAM, UK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are being studied for the prevention/reversal of Type 1 and Type 2 Diabetes and the treatment of Celiac Disease.Four key value-driving milestones are expected within 18 months, including clinical proof of concept in multiple indications. Estimated cash runway for combined company exten
  Sep 30, 2025 - $BRNS
• Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments
  The final cohort of the single ascending dose (SAD) part of the Phase 1 AVALON trial initiated, with the SAD data readout expected early in the fourth quarter of 2025;The multiple ascending dose (MAD) part of the AVALON trial initiated; Available resources and cash runway guidance into 2027 remains unchanged. GERMANTOWN, Md., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), an immunology and inflammation (“I&I”) company focused o
  Aug 7, 2025 - $BRNS
• Broadwind Leads The Charge With 2 Other Prominent Penny Stocks
  As major U.S. stock indexes hover near all-time highs, investors are navigating a landscape shaped by robust earnings reports and ongoing geopolitical developments. Amidst this backdrop, the concept of penny stocks—though somewhat outdated—remains a relevant investment area for those seeking opportunities in smaller or emerging companies. These stocks can offer potential growth at lower price points, especially when backed by strong financial health and solid fundamentals. In this article, we...
  Jul 17, 2025 - $BRNS
• Q2 Virtual Investor Summit: Presentations Available Now
  NEW YORK CITY, NY / ACCESS Newswire / June 25, 2025 / The Q2 Investor Summit presentations are now live and available for on-demand viewing! Held on June 10, the summit featured dynamic presentations from a wide range of microcap companies, each offering ...
  Jun 25, 2025 - $BRNS
• Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025
  OXFORD, GB AND GERMANTOWN, MD / ACCESS Newswire / June 9, 2025 / Barinthus Biotherapeutics plc announced that Bill Enright, CEO, will be presenting at the Investor Summit Virtual taking place on June 10. About Barinthus Biotherapeutics Barinthus Biotherapeutics ...
  Jun 9, 2025 - $BRNS
• Metalpha Technology Holding And 2 Other Promising Penny Stocks
  Amidst the backdrop of China-U.S. trade tensions, the U.S. stock market has experienced fluctuations, with indices like the S&P 500 recently posting their best monthly performances since 2023. In such a volatile environment, investors often seek opportunities that offer potential growth without excessive risk. Penny stocks, typically representing smaller or newer companies, continue to be relevant for those looking to uncover hidden value at lower price points. This article explores three...
  Jun 2, 2025 - $BRNS